What you need to know:

• Skin health is seeing rising attention, with early and mid-stage startups using telehealth business models, AI analytics, and biotech to create new solutions.
• Emerging focus areas span virtual dermatologist consultations, AI-enabled remote skin health monitoring, at-home skin analysis for care routines, new healthy aging therapies, and microbiome-balancing solutions.
• Looking ahead, watch for solutions using smartphones for at-home diagnostics and AI-enabled analytics to gain traction, driven by demand for access to professional, science-based, and personally targeted skin care.

The skin is our largest organ. Maintaining healthy skin is crucial to our overall health and wellness, particularly given that 1 in 5 Americans will develop skin cancer in their lifetime. 

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post As skin healthcare takes off, here’s where emerging tech players are innovating appeared first on CB Insights Research.

Meanwhile, M&A activity is on the rise, climbing for the second straight quarter in Q3’24.

Based on our deep dive in the full report, here is the TL;DR on the state of digital health:

• Global digital health funding drops 23% QoQ to hit $3.3B in Q3’24, marking the second-lowest quarterly funding level since 2017. This decline comes despite a slight uptick in deal count QoQ. However, the average deal size in 2024 YTD is $17.8M — a 51% increase from the full-year 2023 average of $11.8M. This jump in average deal size, amid a downturn in deals over the same period, reflects that investors are concentrating larger sums on fewer, later-stage ventures.

• Digital health mega-round deals ($100M+ deals) drop slightly in Q3’24, falling from 9 to 7 QoQ. Meanwhile, mega-round funding and share of total funding also declined QoQ, underscoring a more cautious investor approach. Mega-rounds accounted for 30% of total digital health funding in Q3 — down from 44% in Q2. Top Q3’24 mega-rounds (by round amount) included:
  • Women’s health app Flo Health‘s $200M Series C
  • Digital-first health insurance provider Alan‘s $193M Series F

• The US accounts for 52% of digital health deals in Q3’24, down from 61% in Q2. Meanwhile, Europe and Asia both saw their deal shares rise to 21% in Q3. Asia experienced a greater jump in deal share, gaining 7 percentage points QoQ while Europe gained 3. This shift suggests growing investor interest in markets outside of traditional US hubs.

• Q3’24 sees the emergence of 2 new digital health unicorns — both based in Europe. The newest members of the digital health unicorn club are UK-based Flo Health, a women’s health app, and Huma, a remote patient monitoring platform. Against the backdrop of a broader downturn in new digital health unicorns, these births highlight Europe’s growing importance in the digital health landscape.

• Digital health M&A exits continue to climb in Q3’24, rising 23% QoQ to 37. This rising M&A appetite may be partly fueled by established companies seizing opportunities to scoop up innovative technologies amid a challenging funding environment for startups. The largest M&A deal in Q3’24 was LetsGetChecked’s $525M acquisition of digital pharmacy Truepill.

MORE DIGITAL HEALTH RESEARCH FROM CB INSIGHTS

• State of Digital Health Q2’24 Report
• Digital Health M&A: Every second acquisition in 2024 has been an AI company
• The $4.6B opportunity in healthcare: Ambient AI to target clinician burnout
• Analyzing Eli Lilly’s growth strategy: How the pharma giant is leveraging AI and pioneering a direct-to-patient approach
• Prioritizing clinical trials tech: How 16 tech-driven markets stack up across maturity and momentum

The post State of Digital Health Q3’24 Report appeared first on CB Insights Research.

What you need to know:

• Eli Lilly is using technology to reengineer how it develops treatments, leveraging AI to speed up drug discovery.
• The company is investing in novel drug delivery methods, such as targeted delivery systems, to improve treatment efficacy and the patient experience.
• Lilly is rapidly expanding its direct-to-consumer approach through LillyDirect, partnering with telehealth providers and integrating with digital pharmacies to streamline drug distribution and improve patient access.

Eli Lilly is using technology to reengineer how it develops and delivers treatments.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Analyzing Eli Lilly’s growth strategy: How the pharma giant is leveraging AI and pioneering a direct-to-patient approach appeared first on CB Insights Research.

What you need to know: 

• Ambient AI is reducing clinician burnout by autonomously documenting clinical interactions. Physicians are already reporting benefits such as being able to see more patients each month.
• Strategic partnerships, like that between Abridge and Kaiser Permanente, are driving large-scale adoption.
• Tech giants like Microsoft and Oracle are entering the space, making ambient AI a key part of their health IT offerings.

Ambient AI — tech that autonomously monitors and reacts to changes in an environment — could be key to addressing the widespread issue of clinician burnout, which costs the US healthcare system an estimated $4.6B annually.  

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The $4.6B opportunity in healthcare: Ambient AI to target clinician burnout appeared first on CB Insights Research.

Essential resources to understand the future of healthcare:

• • The generative AI in healthcare market map — These tech companies are bringing generative AI into medical research and clinical settings.
  • Pharma AI Readiness Index: Who’s best-positioned for the AI boom? — Assess how prepared top pharmaceutical companies are to adopt and respond to rapidly evolving AI technologies.
  • 6 digital health markets gaining momentum in 2024 — We analyzed early-stage investment trends to uncover which digital health markets — from telepsychiatry to virtual & hybrid women’s healthcare — are quickly evolving and how.
• 
  • The Digital Health 50 — Here are the world’s most promising digital health startups.
  • Big Tech in Healthcare — How Amazon, Google, Microsoft, & Nvidia are looking to transform drug R&D, primary care, and more.
  • State of Digital Health Q2’24 Report — Funding in digital health drops, but larger check sizes and an uptick in exits highlight bright spots for the industry in Q2’24.
• 
  • Longevity tech market map — 64 promising startups across 12 categories aiming to expand lifespans, from human cryopreservation to cellular reprogramming.
  • Digital Health AI M&A — Every second acquisition in 2024 has been an AI company; here’s where we’re seeing the most activity.
  • 20 tech trends to watch closely in 2024 — The technology trends that will transform industries as generative AI takes center stage, including several directly impacting healthcare.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Our top digital health research and trends to watch appeared first on CB Insights Research.

This acquisition follows Commure’s Oct 2023 acquisition of another AI-driven provider workflow solution Athelas — which offers revenue cycle management (RCM) and automated documentation services — further bolstering its AI arsenal.

These deals reflect a key trend in healthcare M&A: AI is all the rage. 

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Digital Health M&A: Every second acquisition in 2024 has been an AI company appeared first on CB Insights Research.

Amid the decline, investors have shifted their focus to writing fewer, larger checks for more mature companies in the digital health ecosystem. Meanwhile, their interest in early-stage companies has cooled.

Based on our deep dive in the full report, here is the TL;DR on the state of digital health:

• Global digital health funding declines by 26% QoQ, with funding falling to $2.9B across 235 deals in Q2’24 — the lowest quarterly deal volume seen since 2014. However, the annual average deal size globally is $16.7M in 2024 YTD, up 40% from the average for full-year 2023, signaling that investors are writing fewer but larger checks.

• US deal share grows to 61%, up from 54% in Q1’24. While digital health funding in the US declined by 18% QoQ in Q2’24, the US’ proportion of the global deal volume grew, marked by an increase in mid- to late-stage deal share. Median deal size is also up in the US in 2024 so far — sitting at $7.5M vs. $4.6M in full-year 2023.

• Mid-stage deal share jumps to 26% in 2024 YTD, while early-stage deal share falls by 14 percentage points. Early-stage deals have consistently accounted for 60%+ of all digital health deals in recent years. However, in 2024 YTD, early-stage deal share has dropped to 51% as mid- and late-stage deals have captured more investor interest. In the US, early-stage deal share has fallen to 45% in 2024 YTD vs. 62% in full-year 2023.

• $100M+ mega-rounds drop off in Q2’24 but are more varied across the digital health landscape. Digital health mega-rounds dropped from 8 in Q1’24 to 5 in Q2’24. While mega-rounds were focused on biotech in Q1’24, they were more spread out in Q2’24, spanning areas like care navigation, ultrasound tech, and value-based care tools. The largest deal of the quarter ($200M Series D) went to Foodsmart — a telenutrition company focused on chronic disease management.

Source: CB Insights — Foodsmart Funding Insights

• Digital health exits increase in Q2’24, rising from 26 to 32 QoQ. AI-driven platforms were the highlight here, with Tempus (precision medicine) and XtalPi (drug R&D) going public via IPO and Nuvo Group (remote pregnancy monitoring) going public via SPAC. Digital health M&A exit activity also picked up in Q2’24, especially in Europe, which saw M&A deals jump from 5 to 10 QoQ. Globally, virtual care, provider workflow tools, and drug R&D platforms were key categories for M&A in Q2’24.

The post State of Digital Health Q2’24 Report appeared first on CB Insights Research.

From ambient documentation to surgical tools and digital wound care, AI solutions are helping providers focus on patients, improve diagnostics, and find new ways to perform surgeries and other procedures.

To determine which health systems are most prepared for the shift, CB Insights has launched the Hospital AI Readiness Index.

We looked at the top private-sector health systems in the US (by hospital count) and ranked them based on how prepared they are to adapt to a rapidly evolving AI landscape across 2 key pillars: innovation and execution.

• Innovation: The innovation score measures a health system’s track record of developing or acquiring novel AI capabilities. This score is based on CB Insights data including patents, acquisitions, and deal-making activity. It also considers the presence of an AI-dedicated research center.
• Execution: The execution score measures a health system’s ability to bring AI-powered products and services into clinical practice as well as deploy AI internally across business and back-office functions. This score is based on CB Insights data including business relationships, product launch media mentions, and earnings transcripts.

Below, we present the 25 health systems (inclusive of subsidiaries and venture arms) most prepared for AI.

Want to dive into key data featured in this index? CB Insights customers can check out the links below:

• AI investments
• AI acquisitions
• AI patents

Leaders

Mayo Clinic leads in AI readiness primarily due to its relatively high level of AI innovation. 

Its innovative nature is reflected in part by its patent activity. For example, Mayo has filed 50+ patents across areas like cardiovascular health and oncology. It has also invested in AI-enabled companies addressing a range of use cases in healthcare, from clinical documentation to surgical intelligence.

Intermountain Health and Cleveland Clinic round out the top three. 

Notable activities for these players include Intermountain’s internal development of a real-time clinical decision support platform. Meanwhile, Cleveland Clinic stands out on the execution front due to its high volume of AI-focused business relationships, such as a partnership with PathAI focused on leveraging pathology algorithms to enhance translational research and clinical care.

Source: CB Insights — Cleveland Clinic Business Relationship Insights

Innovation

Innovation scores are based on the presence of an AI-dedicated research center and CB Insights data on AI-related patents as well as acquisitions and deal-making activity since 2019 (as of 5/29/2024).

The most active health system in terms of investment count is Mayo Clinic. Its investments highlight areas where AI is picking up steam in healthcare. For example, at the end of 2023, it participated in a funding round for Abridge — a startup that helps transcribe patient-provider conversations and create clinical notes using generative AI — alongside investors like CVS Health Ventures, the American College of Cardiology, and Kaiser Permanente Ventures. Mayo Clinic has also funded companies like Theator, which combines computer vision and AI to help surgeons draw and act on insights from videos of procedures.

Intermountain Health is the second most active AI investor among evaluated health systems. Via its venture arm, Intermountain Ventures, it backed AI-powered patient engagement platform Gyant, which has since been acquired. Most recently, its venture arm invested in Freenome, which develops blood tests for early cancer detection.

When it comes to patent count, Mayo Clinic and Cleveland Clinic lead the pack. 

One focus area for Mayo Clinic is cardiovascular health. For example, in 2022, it was granted a patent for a system that uses a machine learning model to analyze electrocardiogram (ECG) data and predict the likelihood that a patient will have a stroke. 

Source: CB Insights — Mayo Clinic patents

Meanwhile, Cleveland Clinic was granted a patent for a decision support system that utilizes machine learning to individualize radiotherapy doses, enhancing the precision and effectiveness of cancer treatments.

The evaluated health systems are not overly acquisitive — just one has inked an acquisition in the past 5 years: Providence. In 2019, it acquired Lumedic, which uses blockchain and AI to streamline healthcare revenue cycle management.

Execution

Execution scores are based on CB Insights data including AI-related business relationships, product launch media mentions, and earnings transcripts since 2019 (as of 5/29/2024).

The majority of the health systems evaluated for this ranking have established business relationships with AI-enabled companies.

For example, in 2024 so far:

• Mayo Clinic teamed up with Techcyte to develop a platform that will help healthcare organizations harness AI in their pathology practices.
• Meanwhile, Banner Health worked with Regard to ease the administrative burden on clinicians by automating key tasks, like notetaking and chart reviews.
• Johns Hopkins Medicine partnered with Healthy.io to offer digital wound care services to patients.

Few evaluated health systems have earnings calls, as many are non-profit organizations with different financial reporting requirements than publicly traded companies. However, earnings calls among systems that do hold them reveal how AI is coming into view in a hospital setting. 

For example, Community Health Systems’ EVP of clinical operations, Miguel Benet, highlighted how AI could be deployed to streamline clinical documentation on an earnings call in Q4’23. He also discussed how CHS is using AI to provide patients with relevant information regarding local resources upon discharge — an initiative that has already yielded positive results, such as reductions in length of stay.

Source: CB Insights — Community Health Systems earnings transcripts

Four of the health systems on this list have launched AI-enabled products. 

For example, last year, Intermountain Health developed a platform equipped with real-time clinical decision support tools that leverage AI to improve patient diagnosis and treatment. Just a few months ago, CommonSpirit Health launched Insightli, an internal AI assistant capable of generating written content.

The post Which hospitals have the most AI innovation? Our AI Readiness Index shows Mayo Clinic is leading the pack appeared first on CB Insights Research.

These leaders are harnessing their existing offerings — in areas like cloud computing, AI, and hardware — to service healthcare providers and pharmaceutical companies.

While big tech players are competing with each other in this landscape, they are also carving out distinct strategies: 

• Amazon is going deeper into primary and specialized care.
• Google is amassing troves of health data, which could play a role in its biotech bets. 
• Microsoft is equipping healthcare organizations with AI tools to improve clinical research, drug R&D, and care delivery.
• Nvidia’s long-standing hardware dominance positions it to play a major role in the future of smart hospitals. 

This report uses CB Insights datasets like investments, acquisitions, business relationships, patents, buyer interviews, company scouting reports, and more. Learn more about our data here.

The post Big Tech in Healthcare: How Amazon, Google, Microsoft, & Nvidia are looking to transform drug R&D, primary care, and more appeared first on CB Insights Research.

As a result, femtech categories — spanning hardware, software, and tech-enabled services — have emerged to address a variety of women’s health needs, from menstruation and maternity to menopause and pelvic health. 

To help strategy teams prioritize femtech markets in their planning decisions, we plotted markets using CB Insights’ TECH framework, which scores markets across 2 dimensions:

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The femtech market ranking: Where women’s health technology is maturing, emerging, and plateauing appeared first on CB Insights Research.

It’s tackling the issue on all fronts, from investing in AI-enabled care models via Google Ventures, to forging partnerships through its Google Cloud division, to launching new products that tailor generative AI to healthcare use cases.

These moves seek not only to address the challenges facing the sector, but also to strategically differentiate Google from big tech peers like Nvidia, Microsoft, and Amazon — all of whom are making concerted efforts to integrate AI into healthcare.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Analyzing Google’s healthcare growth strategy: Can the tech giant become the sector’s go-to AI provider? appeared first on CB Insights Research.

Digital health funding grew 48% quarter-over-quarter in Q1’24. This growth was supported by an increase in $100M+ mega-rounds, which were largely directed at biotech startups and other players leveraging AI.

Despite the increase, however, total funding still came in below pre-pandemic levels in Q1’24. Meanwhile, deal count continued to trend down.

Based on our deep dive below, here is the TL;DR on the state of digital health:

• ​Global digital health funding increases 48% QoQ to reach $3.7B in Q1’24. However, funding was still down 12% vs. Q1’23 and 63% vs. Q1’22. Meanwhile, digital health deal count declined in Q1’24, dropping to its lowest quarterly level since 2014.
  
  
• Funding to US digital health startups rises 44% QoQ. However, the US also saw deals drop to 144 — the fewest in a quarter since 2013. Despite the decline, the US still saw the majority of global digital health deals (53%) and funding (70%) in Q1’24. The US also secured 6 out of 7 digital health mega-rounds in the quarter.
• Average digital health deal size is up 38% in 2024 so far. After dropping from $23.1M in 2021 to $11.9M in 2023, average deal size is up to $16.4M in 2024 so far. This is being driven in part by the resurgence of mega-round deals. In Q1’24, these deals accounted for their second-highest share of quarterly funding since 2022.
• Digital health sees 7 $100M+ mega-rounds in Q1’24. Digital health mega-round deals rebounded QoQ in Q1’24. The largest digital health deal of the quarter went to Freenome — a biotech company focused on cancer detection. While biotech drove the top deals, Q1’24 mega-rounds were spread across the digital health industry, from biomedical NLP to robotics for microsurgery.
• No new unicorns (private companies valued at $1B+) emerge. While Freenome added $1B to its valuation following its Series F mega-round in February 2024, the company had already attained unicorn status in 2020. Among Q1’24 mega-round earners, Abridge saw the largest increase in disclosed valuation. It reached an $850M valuation — up 350% from October 2023.

The post State of Digital Health Q1’24 Report appeared first on CB Insights Research.

The tech giant found a major entry point into healthcare workflows when it acquired Nuance for $19.7B in 2022. It followed up on this by expanding its existing relationship with leading EHR vendor Epic to introduce generative AI across clinical workflows, with the aim of improving provider efficiency and mitigating staffing shortages.

Microsoft’s recent relationships also point to an increasing focus on developing and deploying generative AI in the pharmaceutical industry. The tech behemoth is partnering with and investing in startups in drug development, where early applications of generative AI have seen especially strong investor and commercial traction.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Analyzing Microsoft’s healthcare growth strategy: How the software giant is betting generative AI will transform the sector appeared first on CB Insights Research.

For instance, diseases that predominantly affect women, such as autoimmune diseases, have been slower to receive funding and research attention.

In recent years, a growing number of femtech startups have emerged to address the issues facing women’s health, and these startups are gaining substantial investment as a result.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The femtech market map appeared first on CB Insights Research.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post 6 digital health markets gaining momentum in 2024 appeared first on CB Insights Research.

Based on our deep dive below, here is the TLDR on the state of digital health:

• Global digital health funding halved for the second straight year in 2023, while deals dropped by more than a third. With just $13.2B raised across 1,397 deals in 2023, funding and deals fell to their lowest levels since 2016 and 2014, respectively. Amid the downturn, the US held its leadership position, attracting more than half of all deals.
• Despite the drops, median deal size remained at $4M — the highest on record. While median digital health deal size has trended up for more than a decade, venture deal sizes more broadly have deflated since 2021.
• Mega-rounds have all but disappeared from the digital health realm. There were just 3 $100M+ rounds in Q4’23 — the lowest count since 2016. On an annual basis, mega-round count hit 20 for all of 2023, falling well below even the quarterly average for 2021 (37 deals per quarter).
• The digital health unicorn herd started to shrink in 2023. Unicorn loss is outpacing unicorn births — a trend driven by a mix of startup exits, down rounds, and shutdowns. Despite the emergence of 4 new unicorns in 2023, digital health’s total unicorn count dropped from 97 to 94 over the course of the year. 
• Digital health M&A nearly doubled in Q4’23, indicating that consolidation is picking up in the market. If funding remains sparse and IPOs remain largely out of reach, M&A will become an increasingly attractive option for cash-strapped digital health startups.
• After falling out of the top investor rankings, Andreessen Horowitz returned to tie for the top spot in Q4. The investor backed 5 unique digital health companies in Q4’23, tying Plug and Play Ventures for the title of “most active.” Thanks to its digital health bets in Q4’23, a16z added yet another unicorn to its portfolio.
• Care delivery & navigation tech held on to its funding crown in Q4’23. With $837M raised in Q4’23, care delivery & navigation tech remained the top-funded digital health sector. It was followed by monitoring, imaging, and diagnostics tech with $501M.

Below, we’ll explore these themes across 7 charts.

Spurred by the onset of the Covid-19 pandemic — as well as the broader tech boom — digital health funding skyrocketed to unprecedented highs in 2021. However, as the pandemic has faded from public imagination, digital health startups have watched funding halve with each passing year, dropping by 52% year-over-year (YoY) in 2022 and 48% in 2023.

At $13.2B, digital health funding for 2023 stood at its lowest level since 2016. Quarterly funding levels have yet to give any indication of a recovery. Dollars to the space fell every quarter in 2023, dropping by 44% from Q1’23 to Q4’23. With just $2.3B raised in Q4’23, digital health startups saw their lowest quarterly total in 8 years.

While no major global region was spared from the downturn, Asia was hit the hardest. In 2023, the continent saw greater YoY drops in funding (-55%) and deals (-46%) than both the US and Europe. While US funding didn’t fare much better — nearly halving last year — the country continued to lead digital health funding by a significant margin, securing nearly 70% of global equity dollars to the space. Unsurprisingly, US-based startups also led on a quarterly basis, even grabbing all 10 top digital health deals in Q4’23. 

While funding has been falling at an even pace since 2021, the downturn in dealmaking is only accelerating with the pandemic in the rearview mirror. Deals to digital health startups dropped by 19% YoY in 2022 and 38% in 2023. Over the course of 2023, digital health startups raised just 1,397 deals — the lowest annual count in 9 years. Quarterly deal count in Q4’23 (243 deals) also hit its lowest level since 2014.

Although digital health investors may be more hesitant to strike a deal now than in 2021, they are putting even more skin in the game where they do see value. Median equity deal size remained steady at a record high of $4M in 2023, representing an 8% increase from the heady days of 2021. This stands in stark contrast to venture at large, which saw a 22% decrease in median deal size over the same period. In digital health, the rise in deal size is particularly pronounced among Asia- and Europe-based startups — both groups have watched median deal size climb over the past 2 years.

Digital health investors may be willing to bet more cash on promising startups, but the upper dollar limit for many has dropped. Mega-rounds (deals worth $100M+) have all but disappeared from the digital health landscape. In Q4’23, just 3 of these deals were inked — the lowest count since 2016. Alongside deal count, quarterly mega-round funding also dropped to an 8-year low of $400M.

Digital health mega-round funding has fallen even further than funding to the space at large. It was down by 96% from its Q2’21 peak in Q4’23, while broader digital health funding decreased by 85% over the same period. So while mega-rounds regularly contributed more than half of the market’s funding in 2021, that share dropped to just 17% in Q4’23 — the lowest since 2019.

The post State of Digital Health 2023 Report appeared first on CB Insights Research.

On the drug R&D front, pharma players are using the tech to design new drugs in a fraction of the time. For instance, Insilico Medicine has brought an AI-generated drug for idiopathic pulmonary fibrosis to Phase II human clinical trials — in about half the time it would take without AI. Startups here saw a flurry of exit activity in 2023 as incumbents race to get involved.

Meanwhile, in the hospital setting, genAI is helping summarize complex doctor-patient interactions, make EHR entries more precise, and enhance diagnostic imaging. Cloud giants like Microsoft and Amazon have announced clinical documentation services that allow providers to automatically create medical notes, while EHR leader Epic has partnered with Microsoft to integrate genAI tools into its EHR system. 

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The generative AI in healthcare market map appeared first on CB Insights Research.

Companies helping women better deal with menopause symptoms raised $230M in equity funding in 2023, up 22% from 2022. This accounted for over a third of all women’s health funding — which plummeted from $1.4B to $648M over the same period. 

Investors see clear growth potential for menopause care — driven by unmet demand for access to medical services specifically for menopause symptoms and by employers becoming more willing to pay for menopause care services as part of employee benefits packages.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Menopause care funding surged in 2023, but startups in the space face long-term risks appeared first on CB Insights Research.

Healthcare isn’t an entirely new sector for Nvidia. It invested in healthcare-focused computer vision startup Zebra Medical Vision, for instance, back in 2017.

In the past few years, however, its investments and partnerships have coalesced into a clear strategy, as the chipmaker builds on its work in advanced computing to lay the foundation for next-gen AI applications in health IT. For instance, it has redoubled efforts in areas like edge computing, which makes it easier to deploy AI in care settings where broadband internet connectivity is limited or nonexistent.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Is Nvidia the next big health IT vendor? How the chipmaker is building a healthcare AI ecosystem appeared first on CB Insights Research.

Hims & Hers is a rare SPAC that has not cratered in the public markets.

Ro, a telehealth platform which remains private, was last valued at $7B in February 2022. However, this valuation is likely somewhat inflated given it came towards the end of the fundraising boom.

Why should Hims and Ro merge?

• Would create one of the largest telehealth platforms with diverse health services.
• Combines Hims’s wellness products with Ro’s diagnostic and treatment capabilities.
• Forms a more formidable player in the digital health sector.

Find our next M&A prediction in this series — Shopify acquires Stripe — here.

The post 2024 prediction: Hims merges with Ro appeared first on CB Insights Research.

Mental health tech solutions have emerged to meet the skyrocketing patient demand. These range from tele-psychiatry solutions — which aim to expand access to therapy and medication — to workplace wellness platforms that address issues like stress and burnout.

For payers and providers, mental health tech opens up opportunities to provide cost-efficient and preventative care, driving down the cost of treating each patient in the long term.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The mental health tech market map appeared first on CB Insights Research.

For example, in January 2022, Transcarent raised at a $1.6B valuation — a 3.5x increase from its valuation just 7 months earlier. Additionally, leading companies like Signify Health went public at multi-billion dollar valuations.

Since then, however, some telehealth valuations have plummeted. Public companies like Amwell and Teladoc, which were worth $8.4B and $43.7B, respectively, in early 2021, have watched their market caps drop to $386M and $3.9B in August 2023.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Which telehealth unicorns have the highest valuation per employee? appeared first on CB Insights Research.

At-home lab testing vendors, for instance, allow patients to perform diagnostic tests across a wide range of specialties and follow up online with physicians. Meanwhile, more targeted solutions like smartphone-based skin testing give patients the ability to take pictures of their skin for remote evaluation by dermatologists or AI algorithms.

RPM has proven crucial in reducing hospital readmission rates. For example, the University of Pittsburgh Medical Center reported a 76% decrease in patient readmission rates after implementing remote chronic and post-acute illness monitoring. 

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The remote patient monitoring market map appeared first on CB Insights Research.

To fight this disease, tech companies are supporting patients, providers, and pharma players by developing tools to improve cancer care, diagnosis, and drug discovery. 

Solutions like liquid biopsy screening are less invasive, faster, and more cost-effective than traditional biopsies, while cell behavior simulations can model tumor behavior to speed up drug R&D.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The oncology tech market map appeared first on CB Insights Research.

In the US, for example, only one-third of women with fertility issues have used fertility services, according to the National Health Statistics Reports.

In response, fertility tech companies have entered the market to bridge the divide, and they’ve raised more than $1.5B in equity funding since 2019. While funding has slowed down over the past couple of years, it remains elevated as the demand for fertility services persists.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Fertility tech startups have raised more than $1.5B since 2019 appeared first on CB Insights Research.